JANX logo

Janux Therapeutics Inc. (JANX)

$10.92

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on JANX

Market cap

$668122914

EPS

-1.59

P/E ratio

--

Price to sales

46.85

Dividend yield

--

Beta

2.436328

Price on JANX

Previous close

$11.37

Today's open

$11.28

Day's range

$10.73 - $11.32

52 week range

$10.73 - $35.34

Profile about JANX

CEO

David Campbell

Employees

113

Headquarters

San Diego, CA

Exchange

NASDAQ Global Market

Shares outstanding

61183417

Issue type

Common Stock

JANX industries and sectors

Healthcare

Biotechnology & Life Sciences

News on JANX

Janux Therapeutics, Inc. (JANX) Discusses JANX011 Phase 1 Healthy Volunteer Data and Autoimmune Development Strategy Transcript

Janux Therapeutics, Inc. ( JANX ) Discusses JANX011 Phase 1 Healthy Volunteer Data and Autoimmune Development Strategy November 9, 2026 8:30 AM EST Company Participants David Campbell - President, Co-Founder, CEO & Director Conference Call Participants Chad Rubin Matthew Phipps - William Blair & Company L.L.C., Research Division Joshua Schimmer - Cantor Fitzgerald & Co., Research Division Jeffrey LaRosa - Leerink Partners LLC, Research Division Oliver McCammon - LifeSci Capital, LLC, Research Division Xiaochuan Dai - UBS Investment Bank, Research Division Presentation Operator Welcome to Janux Therapeutics Janux011 Phase I Healthy Volunteer Data and Autoimmune Development Strategy Call.

news source

Seeking Alpha • Nov 9, 2026

news preview

Janux Therapeutics Announces Positive Initial Phase 1 Data for JANX011 in Healthy Volunteers, Supporting Planned Development in Patients with Autoimmune Disease

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced initial clinical results from the Phase 1 study of JANX011 in healthy volunteers and outlined its planned clinical development strategy in autoimmune diseases. JANX011 is the first program from Janux's proprietary Adaptive Immune Response Modulator (ARM) platform to enter clinical development. The ARM platfo.

news source

Business Wire • Nov 9, 2026

news preview

Janux Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the quarter ended September 30, 2026, and provided a business update. “During the third quarter, we continued to execute across our clinical portfolio, including dosing the first patient in the Phase 1 study of JANX013 in combination with JANX007,” said David Campbell, Ph.D., President a.

news source

Business Wire • Nov 5, 2026

news preview

Janux Therapeutics, Inc. (JANX) Reports Q3 Loss, Beats Revenue Estimates

Janux Therapeutics, Inc. (JANX) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to a loss of $0.39 per share a year ago.

news source

Zacks Investment Research • Nov 5, 2026

news preview

Janux Therapeutics to Host Virtual Event Presenting Initial Phase 1 Clinical Data for JANX011 in Healthy Volunteers

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX), a clinical-stage biopharmaceutical company developing next-generation immunotherapies, today announced that it will host a virtual event on Monday, November 9, 2026, at 8:30 a.m. ET.David Campbell, Ph.D., President and Chief Executive Officer, will present initial clinical data from the Phase 1 single-ascending-dose study of JANX011 in healthy volunteers. The presentation will review safety, pharmacokinetics and pharmacodynamic.

news source

Business Wire • Nov 2, 2026

news preview

4 Prostate Cancer Drug Stocks to Watch During Awareness Month

Pfizer, Novartis, Janux Therapeutics and Candel Therapeutics offer varied prostate-cancer exposure, with established drugs and clinical or regulatory catalysts.

news source

Zacks Investment Research • Sep 15, 2026

news preview

Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX), a clinical-stage biotechnology company developing tumor-activated immunotherapies, today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating JANX013, Janux's novel PSMA-targeted tumor-activated CD28 co-stimulatory bispecific, in patients with metastatic castration-resistant prostate cancer (mCRPC). The program is initially being developed in combination with JANX007, with the goal of furthe.

news source

Business Wire • Sep 14, 2026

news preview

JANX Shares Gain 19.1% in 3 Months: Here's What You Need to Know

Janux stock climbs 19.1% in three months as pipeline progress, upcoming catalysts and a strong cash position boost investor confidence.

news source

Zacks Investment Research • Aug 21, 2026

news preview

Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the quarter ended June 30, 2026, and provided a business update. "During the second quarter we continued to execute across our clinical portfolio while preparing for multiple upcoming milestones," said David Campbell, Ph.D., President and Chief Executive Officer of Janux. "Enrollment con.

news source

Business Wire • Aug 6, 2026

news preview

Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Lags Revenue Estimates

Janux Therapeutics, Inc. (JANX) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to a loss of $0.55 per share a year ago.

news source

Zacks Investment Research • Aug 6, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Janux Therapeutics Inc.

Open an M1 investment account to buy and sell Janux Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in JANX on M1